High-count Monoclonal Lymphocytosis Linked to Higher Risk for Non-hematologic Cancer

Share this content:
Patients with high count monoclonal B-cell lymphocytis seem to be at increased risk for non-hematologic cancer.
Patients with high count monoclonal B-cell lymphocytis seem to be at increased risk for non-hematologic cancer.

Patients with high count monoclonal B-cell lymphocytis (MBL) seem to be at increased risk for non-hematologic cancer, according to an article published online ahead of print in Leukemia.1

Researchers identified all individuals with high-count MBL at the Mayo Clinic between 1999 and 2009 and compared rates of non-hematologic cancer among with patients with CLL, clinic control patients, and flow cytometry controls.

RELATED: Genetic Variants, Treatment Response in B-Cell Lymphoma Investigated

With a median follow-up of 4.6 years, 13% of people with high-count MBL had developed non-hematologic cancer, compared with 4% clinic controls (comparison MBL P<0.0001), 4% flow controls (comparison MBL P=0.0001), and 12% of patients with CLL (comparison MBL P=0.82).

These findings further reinforce that high-count MBL “has a distinct clinical phenotype despite low risk of progression to CLL,” the authors concluded.

Reference

  1. Solomon BM, Chaffee KG, Joreira J, et al. Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. [published online ahead of print August 27, 2015]. Leukemia. doi: 10.1038/leu.2015.235.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters